Twins Study Busts Cannabis Gateway Theory

Legal access to recreational cannabis has no effect on increasing the probability of disorders using alcohol or illicit drugs, according to a recent study of twins.

In a recent report published by the journal Psychological Medicine, researchers observed data gathered from observing twins living in Colorado and Minnesota. They found no link to legal access to marijuana with the likelihood of developing substance abuse problems. 

“Cannabis legalization was associated with no other adverse outcome in the co-twin design, including cannabis use disorder,” researchers found. “No risk factor significantly interacted with legalization status to predict any outcome.”

“We found mostly a lot of nothing, which I think is personally interesting,” lead researcher Stephanie Zellers added. “I think this is a case where we don’t find much is actually more interesting maybe than finding a bunch of results.”

The study also noted that residents living in legal cannabis states didn’t appear to show an increase in problems associated with mental health, relationships, work and finances.

“Recreational legalization was associated with increased cannabis use and decreased alcohol use disorder symptoms but wasn’t associated with other maladaptations,” researchers wrote. “These effects were maintained within twin pairs discordant for residence. “Moreover, vulnerabilities to cannabis use were not exacerbated by the legal cannabis environment.”

Access to Legal Market

Zellers and her research team observed 240 pairs of twins where one lives in the legal state of Colorado while the other lives in Minnesota, where cannabis remains prohibited. Now aged 24 to 49, the participants have provided data on their personal use of alcohol, tobacco, cannabis and several illicit drugs, as well as measures of “psychosocial health” since adolescence.

“This co-twin design automatically controls for a wide range of variables, including age, social background, early home life and even genetic inheritance” that can influence health outcomes, said co-researcher John Hewitt, professor of psychology and neuroscience at CU Boulder. “If the association holds up, it provides strong evidence that the environment, in this case legalization, is having an impact.”

“There’s lots of things that could explain why one person is behaving one way or why people of one state behave one way compared to another,” Zellers said. “But with twins, we were able to rule out so many of those alternatives—not everything, but a lot of them.”

The recent study acted as a follow-up to prior research that found an increase in adult cannabis use where states have allowed recreational use. Despite the rise in use, however, the team found no relationship to a spike in cannabis abuse or addiction.

“Obviously the cannabis use increases, but we didn’t see an increase in cannabis-use disorder, which is a little surprising,” Zellers said. “We didn’t really see changes in how much people were drinking or using tobacco. No large personality or workplace or IQ differences or anything like that.”

But while cannabis use increased in legal situations, twins living in such areas were also less likely to drive drunk or develop alcohol use disorders.

“You’re combining drinking with something that could be physically unsafe,” Zellers said. “The residents of legal states do that less, which is interesting and maybe something a little unexpected.”

Disproving the Cannabis Gateway Theory

The findings also reject the gateway drug theory that using marijuana only leads to using stronger substances.

“We asked in the last 12 months have you tried or used heroin, prescription opiates, cocaine, methamphetamine, hallucinogens—kind of the whole 11 or 12 categories of illicit drugs,” Zellers said. “And there’s no difference there. People living in a state with legal cannabis, they’re not necessarily transitioning on to more illicit drugs.”

The results are quite promising but are far from an absolute conclusion. The study does have several limitations, as it focuses on adults, and few of whom consider themselves as heavy users.

“Our sample is an adult community sample broadly characterized by low levels of substance use and psychosocial dysfunction,” the researchers wrote. “This limits our ability to generalize relationships between legalization, outcomes and risk factors for the individuals at greatest risk.”

The post Twins Study Busts Cannabis Gateway Theory appeared first on Cannabis Now.

Mushrooms Legality, Psychedelics Funding, Cannabis Industry Mass Layoffs, and more – The Cannadelics Sunday Edition

Welcome to the Cannadelics Sunday Edition, our weekly newsletter sent to our readers every Sunday morning with the leading stories of the week. This week the main articles were about Mass layoffs in Cannabis industry, Psychedelics funding, Global Mushrooms Legality, Psychedelics events, Cannabis use disorder, Drunk experiences, drugs in Cuba and more

In addition the main stories of the week, each newsletter also includes three attractive deals, from our Deal Of The Day section. As always, the best Cannabis and Psychedelics offers are reserved for our subscribers, so subscribe here or use the sign-in form below.


 Keep yourself updated with the latest Cannabis & Psychedelic stories, such as the global mushrooms legality and more: 
Subscribe to our newsletter


The Cannadelics Sunday Edition (2/5/2023) – Psychedelic Funding, Global Mushrooms Legality, Cannabis Industry Mass Layoffs, and more

Hi,

Welcome to the Cannadelics Sunday edition, going out every Sunday with the top stories from the cannabis and psychedelics industries. This week we have a mixed bag of stories as well as a few deals from our deal-of-the-day segments.

Thanks for stopping by!


DEAL OF THE DAY #1:

25% Off 5g Disposable Vape (5 Gram)

25% Off 5g Disposable Vape (5 Gram)

Looking for a powerful and convenient vaping experience? Check out the 5g Disposable Vape! This innovative device offers a potent blend of THCADelta 9P, and HHCP-O distillate paired with live resin terpenes. Made from hemp-derived cannabinoids, this 5 gram disposable vape is fully legal and offers a variety of tasty flavors like Alaskan Lights, Desert Diesel, and Tropical Zkittlez. 

Take advantage of our deal of the day and save an extra 25%, using the Delta25 coupon code. 

Click here to buy the new 5g Disposable

(With Delta25 coupon code)


THE WEEK IN REVIEW:

This week we have a pretty even mix of both cannabis and psychedelics news. A few popular topics explore psychedelic funding, global amanita muscaria legality, cannabis industry struggles and mass layoffs, and more. Scroll down for these articles and many others!


What Happened in the World of Psychedelics Funding Last Year?

Psychedelics funding, Global Mushrooms Legality
What Happened in the World of Psychedelics Funding Last Year?

One of the trending developments over the last year, is the newfound level of growth and acceptance of psychedelic drugs. One way to determine this growth is by looking at how many states and cities are updating legislation. Another way is by seeing how much money is being raised by different companies and investors. Spoiler alert, it’s a lot… read on to learn about the exact figures.

Continue reading »


Global Mushrooms Legality:

Global Mushrooms Legality: here in the World are Amanita Muscaria Illegal?

amanita muscaria illegal - global mushrooms legality
Global Mushrooms Legality: here in the World are Amanita Muscaria Illegal?

Global mushrooms legality: With Amanita muscaria mushrooms growing in popularity, especially during the last couple of months, many people are wondering if they’re legal to possess in their region. Luckily, in most cases the answer to this is a resounding yes, since only a handful of areas have any type of legislation against these shrooms. But if you live in one of the following five places in the world, then you’re out of luck on buying them legally.

Continue reading »


What Psychedelics Events You Need to Attend in 2023 (Global Edition)

global psychedelics events
What Psychedelics Events You Need to Attend in 2023 (Global Edition)

As the world grows increasingly eager to learn more about psychedelic drugs and their healing properties, we’re seeing a sharp rise in related events where industry professionals can gather with inquisitive consumers to discuss all the most important aspects of this budding market. We’ve already covered some of the more anticipated events going on in the U.S. this year, and now we’re following up with the top 5 global psychedelics events taking place in 2023.

Continue reading »


Psychedelic vs Psychoactive – What’s the Difference?

psychedelic psychoactive, Global Mushrooms Legality
Psychedelic vs Psychoactive – What’s the Difference?

If you read about drugs often, you’ve probably come across the terms “psychoactive” and “psychedelic” quite frequently. Although many publications use them interchangeably, that is incorrect and there are some key differences between the two. The broadest way to describe it, is that all psychedelic drugs are psychoactive, but not all psychoactive drugs are psychedelic.

Continue reading »


DEAL OF THE DAY #2:

Save 25% Discount On Live Resin Delta-9 THC Chocolate 
(Valentine’s Day Special)

Delta-9 THC Chocolate
Save 25% Discount On Live Resin Delta-9 THC Chocolate 

Make this Valentine’s Day extra special with a 25% discount on Delta-9 THC chocolate bars. Use the Delta25 coupon code to save on Milk, Dark, or Cookies & Cream flavors for a romantic evening with your loved one. 

Don’t miss out on this Deal of the day and make this Valentine’s Day unforgettable.

TIP: Get 25% discount when using the Delta25 coupon code.

Click here to save on Live Resin Delta-9 THC Chocolate

(With Delta25 coupon code)

Additional Reading:

A few more articles for your reading pleasure.

Is Cannabis Use Disorder Really a Thing?

Can cannabis use lead to a disorder?
Is Cannabis Use Disorder Really a Thing?

The general consensus on cannabis has always been that it’s not really addictive. And that’s definitely true to an extent; we can say without a doubt that it’s not physically addictive and does not cause any type of illness or symptoms of withdrawal when someone stops using. That being said, can it be mentally addictive? That’s what the medical community aims to answer by exploring the possibility of “cannabis use disorder”.

Continue reading »


Do Different Alcoholic Drinks Cause Different Drunk Experiences?

alcoholic drinks
Do Different Alcoholic Drinks Cause Different Drunk Experiences?

There are hundreds of different types of alcohol, and many people swear that certain types of liquor produce different types of drunk effects. For example, one that immediately comes to mind is tequila. I’ve lost count of the number of times I’ve heard someone say that tequila makes them ready to fight. On the flip side, many believe that whiskey offers an extra-confident drunk experience. Some will argue that there’s no logic behind this, that it’s simply the amount of alcohol within the drinks and the speed at which you metabolize them. But maybe there’s more going on here.

Continue reading »


Mass Layoffs Continue in Cannabis Industry

Global Mushrooms Legality, Mass Layoffs
Mass Layoffs Continue in Cannabis Industry

One surefire way to know if there are problems within in industry is by looking at the hiring patterns. When an industry is doing well, more jobs open up and salaries improve. When an industry is struggling, jobs are lost and pay gets cut. For several months, mass layoffs have been going on in the cannabis industry, signaling major problems with few possible solutions.

Continue reading »


My 2 Week Cuba Experience: Is It really the Anti-drug Capital of the World?

cuba anti-drug
My 2 Week Cuba Experience: Is It really the Anti-drug Capital of the World?

Cuba is a beautiful, underrated, and very misunderstood country. This country hosts every type of terrain one could imagine, making it perfect for hiking, camping, and wildlife photography. There are some amazing beaches to lounge at and soak up the scenery. And if you want to get a feel for 1950s American cars, then Cuba is the perfect place for a vacation. However, if you’re the type of person who likes to get high on vacation, then this little island is a place you may want to avoid.

Continue reading »


DEAL OF THE DAY #3:

25% Off 2500mg Extra Strength Gummies

Tropical Kush extra strength gummies
25% Off 2500mg Extra Strength Gummies

Try the 2500mg “Extra Strength Gummies” today and save with the Delta25 coupon code. 

These gummies pack a powerful punch with 125mg of Delta 8, Delta-9 THC, and THC-P in each one, making them a high-potency option compared to standard gummies that range from 2.5 to 10 milligrams or more. One gummy is enough for 2-3 people, so grab some friends and get ready for a wild time. 

Don’t miss out on the Deal of the day, which includes a 25% discount on these extra strength gummies when you use the Delta25 coupon code.

Click here to save on 2500mg Extra Strength Gummies

(With Delta25 coupon code)

Best Deals On Amanita Muscaria Gummies

Global Mushrooms Legality, Amanita Muscaria Gummies
Best Deals On Amanita Muscaria Gummies

Finding legal psychedelic products is not an easy task, as most of them are illegal to buy or to use. However, while Psylocibin-based magic mushrooms are only making their first steps to become legal, Amanita Muscaria mushrooms are already 100% legal.  These great legal mushrooms offer you a safe entry to to the world of psychedelics.

TIP: Use code Delta25 and get 25% Off and Free Shipping when you buy 3 or more Bottles

Best Deals On Amanita Mushroom Gummies


All the latest from Psychedelics and Cannabis
All the latest from Psychedelics and Cannabis

For all the latest from Psychedelics and Cannabis, follow our Telegram Channel.

 Follow Cannadelics News


News from the Week:

*** Meet Psilomethoxin, the Love Child of Psilocybin and 5-MeO-DMT

*** The Positives and Negatives of Magic Mushrooms

*** 5 Weirdest ways to Consume Cannabis

*** Salvia: Tricks of Use for the Best Experience

*** The Lowdown On Syria As The New Captagon Narco State

*** Why is Everyone ‘Shelving’ their Drugs?

*** Global Mushrooms Legality


We hope you enjoyed this week’s review. We work hard to find and verify the best products, so we may include affiliate links to support the maintenance and development of this site. 

Best, 
The Cannadelics team 

*** Disclaimer: As the legality of cannabinoids and psychedelics changes between state to state, you should always check with your local authorities first.

The post Mushrooms Legality, Psychedelics Funding, Cannabis Industry Mass Layoffs, and more – The Cannadelics Sunday Edition appeared first on Cannadelics.

High Times Cannabis Cup Michigan: People’s Choice Edition 2023

We’re excited to see the product lineup as it begins to develop, but we’re even more excited to announce that we have pumped our number of categories to 20 this year—that’s three more categories than last year! This year we welcome the expansion of Solvent Gummies and Non-Solvent Gummies to the Edibles categories. We’ve also expanded our Medical categories as well to include Medical Concentrates and Medical Infused Pre-Rolls, but you can check out the whole list in its entirety here:

Entry Categories

  1. Rec Indica Flower (4 entries Max per Company) (State-Licensed Adult-Use)
  2. Rec Sativa Flower (4 entries Max per Company) (State-Licensed Adult-Use)
  3. Rec Hybrid Flower (4 entries Max per Company) (State-Licensed Adult-Use)
  4. Rec Pre-Rolls (3 entries Max per Company) (State-Licensed Adult-Use)
  5. Rec Infused Pre-Rolls (2 entries Max per Company) (State-Licensed Adult-Use)
  6. Rec Solvent Concentrates (2 entries Max per Company) (State-Licensed Adult-Use)
  7. Rec Non-Solvent Concentrates (2 entries Max per Company) (State-Licensed Adult-Use)
  8. Rec Distillate Vape Pens & Cartridges (2 entries Max per Company) (State-Licensed Adult-Use)
  9. Rec Non-Distillate Vape Pens & Cartridges (2 entries Max per Company) (State-Licensed Adult-Use)
  10. Rec Edibles: Solvent Gummies (3 entries Max per Company) (State-Licensed Adult-Use)
  11. Rec Edibles: Non-Solvent Gummies (3 entries Max per Company) (State-Licensed Adult-Use)
  12. Rec Edibles: Non-Gummies (3 entries Max per Company) (State-Licensed Adult-Use)
  13. Rec Sublinguals, Capsules, Tinctures + Topicals (3 Entries Max per Company) (State-Licensed Adult-Use)
  14. Medical Indica Flower (4 Entries Max per Company) (State-Licensed Medical-Facility)
  15. Medical Sativa Flower (4 Entries Max per Company) (State-Licensed Medical-Facility)
  16. Medical Hybrid Flower (4 Entries Max per Company) (State-Licensed Medical-Facility)
  17. Medical Pre-Rolls (4 Entries Max per Company) (State-Licensed Medical-Facility)
  18. Medical Concentrates (4 Entries Max per Company) (State-Licensed Medical-Facility)
  19. Medical Infused Pre-Rolls (4 Entries Max per Company) (State-Licensed Medical-Facility)
  20. Medical Edibles (3 Entries Max per Company) (State-Licensed Medical-Facility)

The winners of the High Times Cannabis Cup Michigan: People’s Choice Edition 2022 revealed an outstanding selection of products well-known throughout The Great Lakes State. Brands and companies such as Pro-Gro, FLWRpot, Local Grove, and Canna Boys were just a few of the winners. Feel free to check out the winners from 2021 as well, and you can also look back at the winners of our in-person cannabis cups between 2015-2019.

Can’t wait to get started? Neither can we! Participation for the High Times Cannabis Cup Michigan: People’s Choice Edition 2023 begins on between March 20-30 as the window for submissions. Just in time for 4/20, we’ll have kits available starting on April 15 at participating locations. We’ll give our honored judges just over two months to properly sample and review all of the submissions in their kit, with a deadline of June 25. Finally, just a few weeks after that, we’ll announce the winners on July 9.

Winners receive the coveted High Times Cannabis Cup trophy, a longtime symbol of quality in the cannabis community. It was designed by Alex and Allyson Grey, made from zinc and 24k gold plating.

Judges will analyze the products in their kits through a variety of criteria. For Flower, Pre-rolls, Vape Pens, and Concentrates, judges will take note of a product’s aesthetics, aroma/scent, taste/flavor profile, burnability, effects/effectiveness, and terpene profile. Edibles have a slightly different list of considerations, including packaging and labeling. Finally, Topicals, Tinctures + Capsules judges are asked to review the “ease of use” in addition to other criteria.

Because the competition includes both recreational and medical products, the entry requirements differ slightly. From maximum weight limits on products and number of units submitted, we highly recommend that interested participants who want to submit their products adhere to the following requirements:

Entry Requirements

Recreational:

  • Flower: (228) 1g units. We will not accept any 3.5g entries. 
  • Pre-Rolls & Infused Pre-Rolls: (228) units. Pre-Rolls will be capped at 2g flower-only each.
  • Infused Pre-Rolls will be capped at 3g flower-equivalency or 1g concentrate-equivalency each by METRC equations.
  • Concentrates & Vape Pens: (228) .5g units. We will not accept any 1g entries. Batteries required for Carts.
  • Edibles: (100) units with 100mg THC max.
  • Sublinguals, Capsules, Tinctures + Topicals: (60) units with 500mg THC max.

Medical:

  • Flower: (228) 1g units. We will not accept any 3.5g entries. 
  • Pre-Rolls & Infused Pre-Rolls: (100) units: Pre-Rolls will be capped at 2g flower-only each.
  • Infused Pre-Rolls will be capped at 5g flower-equivalency or 5g concentrate-equivalency each by METRC equations.
  • Concentrates & Vape Pens: (100) .5g units. We will not accept any 1g entries. Batteries required for Carts.
  • Edibles: (100) units with 200mg THC max.

The cost of entry is set at $250 for one entry and $100 each for two (both non-refundable); for entries of three or more, it’s $100 each but the deposits per entry are refundable. If you’re interested in sponsoring the event, there are varied levels of sponsorship including Presenting Sponsorship, Silver Sponsorships, Bronze Sponsorships, and General Sponsorships.

Michigan really came out of the gates strong at last year’s Cup, so we can’t wait to see what these local brands bring to the table this year.

A huge thank you to our official intake partner Green Pharm.

Questions? Email Competition@hightimes.com.

The post High Times Cannabis Cup Michigan: People’s Choice Edition 2023 appeared first on High Times.

The Grounding Duo

Cannabis use can of course heighten your senses and create space for grounding. Some also use it as a tool for connecting with the universal energy that runs through all living things. As cannabis use becomes exponentially accepted, the herb is finding a new home with other alternative holistic therapies. One of these is Reiki, an energy healing practice known for promoting relaxation, clarity and behaving as a complementary therapy for pain, anxiety and mood.

Lauren Mooney is a New York City-based Reiki practitioner who personally uses cannabis and combines her practice with the plant’s powers. She recently taught a Reiki I training course in Los Angeles, where we caught up with her for a fascinating chat. 

Cannabis Now: Hi, Lauren. Would you give our readers a quick description of what Reiki is?

Lauren Mooney: Sure! It’s a Japanese healing modality. In its most basic form, it’s energy healing that has a hands-on aspect to it. Reiki itself is a philosophy. The hands-on healing is such a huge component of it, and a lot of people do it where their hands aren’t completely on you—they’re feeling your auric field, the energy that surrounds us and the energy that we emanate, and everything is made of energy. The way that I describe Reiki is: it’s as if a bunch of radio stations were playing at the same time and then you tune into your own frequency. I believe that’s also true with cannabis because it’s about bringing things into balance, and that balance can really help with so many things. We’re careful in Reiki to not make claims about what Reiki can do because it’s very different for everyone.

Another beautiful aspect of Reiki is its simplicity and that’s what actually makes it challenging to teach because it’s not so much an intellectual thing you learn, it really mostly is experiential. And that also takes me back to cannabis because, like Reiki, cannabis’ benefits are changeable depending on the person. You can’t necessarily make claims like, “Oh, because this strain helped me with my anxiety, it’s going to help my friend with their anxiety.” I like to say Reiki has its own intelligence, and Reiki knows where you need it. 

I helped my mom, who has since passed away, with in-person Reiki. I was about to start doing volunteer meditation and Reiki groups for Gilda’s Club, a cancer support center in New York City right before the pandemic hit, so that started out as virtual, and continues to this day. 

Lauren Mooney combines her reiki practice with cannabis. PHOTO Bailey Robb

Tell me about your journey with cannabis: What got you into it personally, and why did you incorporate it into your practice?

Originally from California, I started smoking recreationally in high school and that was my relationship with cannabis for maybe a decade. 

The recreational dispensaries opened right around the same time that I was getting my mom into using cannabis to help with all the stuff she was going through with her Stage IV melanoma — she had brain tumors and multiple surgeries surrounding that. It was powerful to watch my mom; her leg would be shaking and then I’d give her some CBD tincture and it would literally stop. CBD was getting more popular, so I was already thinking about integrating it topically into my practice. I really think it helps people get into their bodies and slow things down. 

A lot of people look at cannabis as a vehicle to help ground themselves. Can the same be said about Reiki?

I’d say Reiki helps you feel more grounded and slows you down, and that, in turn, can help you with so many different things. I’ve helped people who have had cancer, and it eased some of the anxiety, some of the pain, because slowing down and feeling a bit more grounded really helps with all of that. Being out of our bodies isn’t something that’s unique to having something as extreme as cancer. Being out of our bodies is a symptom of the time, of this virtual insanity that we live in, and obviously the pandemic. I think so many people are basically living out of their bodies and not realizing that they are.

This story was originally published in the print edition of Cannabis Now.

The post The Grounding Duo appeared first on Cannabis Now.

Psychedelics Decriminalization Bill Introduced by California Lawmaker

A California lawmaker on Monday introduced legislation to decriminalize the possession and use of natural psychedelics including psilocybin, the primary psychoactive compound found in magic mushrooms. The bill, introduced by state Senator Scott Wiener, follows similar legislation the San Francisco Democrat introduced last year that was eventually gutted by the legislature in August.

The bill likely faces opposition from law enforcement groups wary of the potential safety risks of easing restrictions on psychedelic drugs, according to media reports. But the measure is backed by mental health professionals and veterans groups that want to allow access to the potential benefits of the compounds.

“Psychedelics have tremendous capacity to help people heal, but right now, using them is a criminal offense,” Wiener said in a statement. “These drugs literally save lives and are some of the most promising treatments we have for PTSD, anxiety, depression, and addiction.”

Psychedelics And Mental Health

Clinical research and other studies into psychedelics such as psilocybin have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, addiction and anxiety. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer.

The legislation introduced on Monday, Senate Bill 58 (SB 58), would decriminalize the possession and use of small quantities of natural psychedelic drugs including psilocybin, ibogaine, mescaline and dimethyltryptamine (DMT). The bill does not legalize the sale of psychedelic drugs. Chad Harman, CEO of psychedelics-focused biotech firm Psycheceutical, said that SB 58 “is a huge advancement for the progress of the psychedelic movement.”

“A careful review of the science and facts surrounding these potentially life-saving compounds is exactly what we have been fighting for, and now the State of California is showing signs of being on board,” Harman wrote in an email. “Not only does this decriminalization bill confirm growing momentum and acceptance from the scientific and medical communities, but it could set the precedent needed for other states to follow suit.”

Bill Follows Similar Measure Introduced Last Year

The measure is similar to legislation introduced by Wiener last year, although the new bill does not include synthetic psychedelics such as LSD or MDMA (ecstasy) that were included in the previous version. The earlier measure, Senate Bill 519 (SB 519), was stripped of its decriminalization provisions by a legislative committee, leaving legislation that only funded a study of the proposal.

“While I am extremely disappointed by this result, I am looking to reintroducing this legislation next year and continuing to make the case that it’s time to end the War on Drugs,” Wiener said in an August statement after learning of the changes made to SB 519. “Psychedelic drugs, which are not addictive, have incredible promise when it comes to mental health and addiction treatment. We are not giving up.”

Joshua Kappel, an attorney with the cannabis and psychedelics law firm Vicente Sederberg, said that Wiener’s new bill could advance the use of psychedelics for mental health, similar to a ballot measure passed by Colorado voters in last month’s midterm elections.

“California’s SB 58 is smart drug policy. John Hopkins, UCLA, and many other universities are discovering that psychedelic-assisted therapy shows promise in treating addiction, depression, and PTSD, Kappel wrote in an email to High Times. “Similar to what the voters recently passed in Colorado through Prop 122, SB 58 decriminalizes the same natural medicines and creates a pathway for supervised therapeutic use.”

Although the bill is supported by some mental health professionals and veterans groups, it is likely to face opposition from law enforcement groups that opposed Wiener’s original bill.

“Without more evidence that these hallucinogenic drugs are no more dangerous than cannabis, we cannot support legalizing them,” the California District Attorneys Assn. wrote in opposition to the previous version of the bill. “Hallucinations can be dangerous to users and bystanders alike, and it is not clear that the benefit of legalizing these drugs outweighs the cost to the common welfare.”

The post Psychedelics Decriminalization Bill Introduced by California Lawmaker appeared first on High Times.

The Danger of Synthetic Cannabis

On the potentially lethal subject of synthetic weed, the news, since legalization, is better, but still not great.

Though not wholly harmless, cannabis itself hasn’t killed anyone through overdose or misadventure. But cannabis prohibition absolutely has a body count. Between 2016 and 2019, at least 61 Americans died after exposure to synthetic cannabinoids, according to recent research conducted by scientists at Washington State University and published in the journal Clinical Toxicology.

Many more have become violently ill or wracked with disturbing mental or psychological trauma after using synthetic cannabis, with more than 64 percent of 7,600 documented exposures over that time frame requiring medical attention, the study found. (These figures don’t capture the full scope of the problem; synthetic cannabinoids are difficult to detect and use is often only detected after the user is in the hospital or the morgue.)

A broad term used generally to describe a range of potent chemicals, intended to mimic natural plant-based cannabinoids and to bind to many of the same receptors—but in some cases, up to 100 times more powerful; the difference in impact comparable “to the difference between a hose hooked up to a fire hydrant versus a faucet with a slow drip,” in the words of Dr. Patricia Frye, a Maryland-based physician and cannabis expert. “Synthetic cannabis” is banned under federal and most state law. (Plant-derived cannabis products created via chemical synthesis, including Delta-8 THC and Delta-10 THC, aren’t in this product category.)

Though not a priority for law enforcement, who still arrested hundreds of thousands of Americans for marijuana possession in 2020, synthetic cannabis is notorious stuff. Most often appearing in large cities, fake weed was the ultimate culprit behind a so-called “zombie outbreak” in 2016 in New York City, after several dozen people exhibited the same troubling dis-associative symptoms after smoking a particularly nasty “incense” product called “AK-47” Karat Gold.

Why would anyone use such dangerous and toxic stuff? And how can policymakers discourage such self-harm and solve what researchers described to Cannabis Now as a “serious health threat”?

The obvious answer will not shock you.

Nobody Really Likes Synthetic Weed, But…

Initially created in labs to understand how cannabinoid receptors work, synthetic cannabis was never intended for use in humans. And perhaps owing to the nasty side effects, synthetic cannabis use isn’t widespread.

Natural cannabis is far more popular. Even the estimated 0.2 to 0.4 percent of the population who do admit to using synthetic weed say they’d prefer natural cannabis.

However, there’s some societal “encouragement” for synthetic cannabis use: synthetic weed prohibition turns out to be difficult to enforce. Synthetic cannabis doesn’t contain THC. Users won’t show THC metabolites on a urine screening, and so drug tests can’t detect synthetic cannabis, the study noted. Thus, anyone in a position to want a buzz and avoid punishment for weed, including US service members, may decide that fake cannabis is worth the risk.

Users profiled in another recent study, from researchers based in Spain, confirm this ready common-sense explanation: Because drug tests don’t search for synthetic cannabinoids, meaning people worried about losing employment, housing, or other opportunities for a positive drug test are willing to risk serious consequences to achieve something like a weed-like buzz.

In other words, drug laws encourage drug users to risk great bodily and mental harm they wouldn’t otherwise risk. They say so themselves.

Synthetic cannabinoids “exist as a by-product of prohibition,” said Dr. Ethan Russo, a physician, neurologist and prominent researcher and author.

“Following the law of unintended consequences, the continued pervasiveness of urine drug screening for employment has stimulated the popular appeal of synthetic cannabinoids, which are not detectable on routine laboratory tests,” Russo told Cannabis Now. “The result is considerable attendant morbidity and mortality.”

In some places, this situation is getting worse. According to the researchers’ findings, published in the journal Frontiers in Psychiatry, “synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis.”

However, that’s not the case in the US, where a simple and popular policy intervention leads to a decline in synthetic cannabinoid exposure (and related deaths and hospitalizations) of more than 37%. Only 5.5% of the synthetic cannabinoid poisonings tracked in the study occurred in states with legalization laws.

This magic public-health solution is allowing people to use cannabis safely and legally.

With Synthetic Cannabis, Legalization Saves Lives

As the Washington state researchers noted, synthetic cannabinoid exposures declined in the US starting in 2016—the same year that four states (California, Maine, Massachusetts and Nevada) legalized adult-use cannabis for adults 18 and over.

Of the exposures that were recorded, most–-56%–-occurred in states “with restrictive cannabis policies at the time of the exposure,” the researchers wrote. When a state passed a law with a more “permissive cannabis policy,” synthetic cannabinoid exposures reduced by 37%, they added.

This amounted to an “association” between “liberal policies (legalization) for natural cannabis and declines in reported synthetic cannabinoid poisonings,” they concluded. “This finding suggests a potential effect of policy change on substance use behaviors that may have long-term public health implications.”

Tracy Klein, the lead researcher and a professor in Washington State University’s College of Nursing, didn’t respond to a request for comment. But other experts, including Frye and Russo and Peter Grinspoon, a Boston-based physician and lecturer at Harvard Medical School, accepted the findings as a strong endorsement for cannabis legalization as a public-health intervention.

Synthetic cannabis harms people, but people don’t want to use it when natural cannabis is available. When natural cannabis is available, people don’t use it. Legalization saves lives. Could there be a simpler proposition?

“The rules of society have created this problem,” Russo said, “one that should no longer exist once a legal and regulated market for cannabis is established.”

“Legalizing cannabis, in the adult-use market, would certainly eliminate the need for experimenting with these potentially deadly chemicals,” Frye said.

The post The Danger of Synthetic Cannabis appeared first on Cannabis Now.

Research Finds Cannabis Effective for Migraines

Cannabis preparations are likely effective at preventing and treating migraines, according to a recently published review of available research. The study, “Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence,” was published in May by the peer-reviewed journal Frontiers in Neurology.

To complete the study, researchers affiliated with the University of Arizona analyzed previously published scientific studies on the effects that cannabinoids have on migraine patients. The objective of the review was to assess the effectiveness and safety of medicinal marijuana in the treatment of migraine in adults.

The researchers identified 12 studies that had been published in Italy and the US involving a total of 1,980 migraine patients. The review revealed that plant cannabinoids have the ability to reduce the number of migraine days and to abort the onset of migraine headaches. The use of cannabis preparations was also associated with significant reductions of pain, vomiting and nausea caused by migraine.

Reducing Migraine Symptoms

Migraine is one of the world’s most common neurological diseases, according to information from the Migraine Research Foundation, affecting approximately 39 million people in the US and about one billion globally. Symptoms, which are often debilitating, can include severe headache, dizziness, nausea, visual disturbances and extreme sensitivity to light or sound. Migraine disease is commonly treated with strong pharmaceutical drugs, although results of treatment vary widely from patient to patient.

Researchers conducting the review of scientific literature determined that after 30 days of use, medical marijuana significantly reduced the number of days patients experienced migraines and the frequency of migraine attacks per month. After six months of use, cannabis significantly reduced the nausea and vomiting associated with migraine.

Medical marijuana was 51% more effective in reducing migraines compared to products that didn’t contain cannabis. Compared to amitriptyline, medical marijuana aborted migraine headaches in 11.6% of patients and reduced migraine frequency. The researchers concluded that there is substantial evidence to support claims that medical cannabis (MC) can be effective at reducing the frequency of migraine and aborting migraine attacks when they occur. The authors of the study also called for more rigorous studies of the effect that cannabis can have on migraine and associated symptoms.

“There is promising evidence that MC may have a beneficial effect on the onset and duration of migraine headaches in adults,” the authors wrote in their conclusion of the study. “However, well-designed experimental studies that assess MC’s effectiveness and safety for treating migraine in adults are needed to support this hypothesis.”

Findings Supported by Previous Research

The new study is consistent with previous research that has shown cannabis can have a beneficial effect for migraine patients. A 2018 study found that cannabidiol (CBD) has several pharmacological properties including acting as an anti-inflammatory, while numerous anecdotal accounts of CBD oil successfully being used for migraine have been reported. Last year, data from a clinically validated survey showed that 86% of respondents reported a decrease in headache impact after using a cannabidiol (CBD) formulation for a 30-day trial period.

The survey was taken by customers using a CBD oil product designed by Axon Relief, a company that creates supplements specifically for migraine sufferers. Known as the Headache Impact Test (Hit-6), the clinically validated survey measures the impact that headaches have on a respondent’s daily life and ability to function.

Participants completed the Hit-6 survey both before and after using the CBD oil. During the 30-day trial period, respondents experienced an average of 3.8 fewer headache days than before using Axon’s CBD oil, a reduction of 23%. Chronic migraine sufferers, defined as people who experience 15 to 29 headache days over a 30-day period, saw a 33% reduction in their headache days.

A participant in the informal Axon study identified only as Glen reported that since “the ’90s I’ve been on constant high doses of carbamazepine and gabapentin. The periodic pain breakthroughs were only controlled by hydrocodone, which always made me feel…uncomfortable,” Glen wrote in a statement from Axon. “What a change CBD oil has made: no more carbamazepine or hydrocodone, and only half the gabapentin—and far better pain control. Pain breakthroughs still happen, but another squirt of Axon CBD, and the pain is gone within 15 minutes. I have no side effects.”

Of the 105 people who participated in the trial for Axon, 15 reported that they were experiencing daily headaches at the beginning of the study. By the end of the 30-day trial period, the number had dropped to 10, a reduction of 33%.

Another review of available research published by the journal Cureus last year also found that medical cannabis could be an effective treatment for migraine. The authors of that study found “encouraging data on medicinal cannabis’ therapeutic effects on alleviating migraines in all of the studies reviewed.”

The post Research Finds Cannabis Effective for Migraines appeared first on Cannabis Now.

Can Cannabis Help Glaucoma Patients?

In 1976, a glaucoma patient named Robert Randall became the first person in the US to be granted legal status as a medical marijuana patient. As a teenager, Randall had been diagnosed with glaucoma and was told by doctors he would likely lose his eyesight before his 30th birthday. After learning of research that indicated THC could be an effective treatment for the disease, he began smoking marijuana. He was subsequently arrested for marijuana cultivation in Washington, D.C., but wasn’t convicted of the charges based on a defense of medical necessity. Thus, the cannabis and glaucoma debate began.

Randall then petitioned the Food and Drug Administration to provide marijuana to treat his disease. In 1976 the FDA approved the petition, later launching the Compassionate Investigational New Drug (IND) program to provide unapproved but promising drugs including cannabis to Randall and patients like him. After receiving shipments of joints from the federal government for 25 years to treat the disease, Randal died at the age of 53 in 2001. During that time, he never lost his eyesight.

What is Glaucoma?

Glaucoma is a group of related diseases of the eyes characterized by a buildup of fluid in the eye resulting in an increase in interocular pressure (IOP). The condition causes pressure on the optic nerve leading from the eye to the brain, leading to a slow loss of vision that can culminate in blindness. Traditional treatments for glaucoma include eye drops, oral medications and surgery. Glaucoma is the leading cause of blindness among people older than 60, according to the Mayo Clinic.

Some research has shown that THC, the cannabinoid largely associated with the classic marijuana “high,” can temporarily reduce IOP, thereby reducing the pressure on the optic nerve. A review of research into cannabis and glaucoma published in 2019 found that five randomized clinical trials found evidence that cannabis could lower interocular pressure. However, the researchers noted that the studies reviewed had design flaws including a small sample size and inadequate controls. But the glaucoma and marijuana studies also failed to compare the effects of cannabis on glaucoma to traditional treatments. The study concluded that randomized clinical trials (RCTs) showing the efficacy of cannabis as a treatment for the disease were necessary before its use could be recommended.

“The studies that were reviewed were highly variable in their methods and patient population selected, and therefore no current evidence supports the use of any form of cannabis to replace existing,” the authors of the review wrote in their conclusion. “Until further research in the form of RCTs with more evidence to support the use of cannabis for lowering IOP, it should not be recommended at this time.”

Noting that the effect that THC has on IOP is short-lived, the authors also added that if patients decide to use cannabis to treat the disease, “they would require frequent dosing, which has the potential to reduce patient adherence and increase side effects of the medication.”

Other research that supports cannabis as a treatment for glaucoma include animal studies that suggested cannabis might improve blood flow to the eyes and promote healing. Animal research also suggests that cannabis may have neuroprotective effects that might prevent damage to the optic nerve.

What About CBD?

However, not all forms of cannabis and glaucoma are effective and shouldn’t be used as a treatment for the disease. A study published in 2006 found that while THC reduced interocular pressure, CBD actually increased IOP. The educational website Glaucoma Today notes that cannabis varietals “with higher THC content can be expected to lower IOP, whereas strains with higher CBD content can be expected to increase IOP. It is therefore important that eye care providers caution patients who are interested in treating their glaucoma with medical cannabis that products with a high CBD content may have a detrimental effect on their disease process.” Patients who choose to treat their glaucoma with cannabis should choose products with negligible amounts of CBD.

Proponents of medical cannabis as a treatment for glaucoma argue that it’s a natural medication with few side effects. Advocates for the glaucoma and marijuana marriage also believe that cannabis can help the pain often associated with glaucoma and reduce the need for surgery. However, the American Academy of Ophthalmology (AAO) maintains that cannabis is not a practical treatment for glaucoma, primarily because of the temporary nature of its effect. The AAO notes that to effectively reduce IOP, patients would have to ingest 18 mg to 20 mg of THC six to eight times daily. The AAO also cites evidence that cannabis might have the opposite effect than intended, increasing IOP and causing additional damage to optic nerve. As a result, the professional group does not recommend the use of cannabis to treat glaucoma.

“Several current, effective treatments for glaucoma are more reliable and safer than marijuana,” the AAO wrote in 2021.

The post Can Cannabis Help Glaucoma Patients? appeared first on Cannabis Now.

Coping with Cannabis: A Soldier’s Experience with PTSD

“One of the difficulties with post-traumatic stress disorder is that the readiness or need for treatment may emerge years after the trauma. Therefore, veterans and their families need long-term treatment options and long-term access to treatment, even if symptoms are not present at their time of discharge.” -William H. Braun, from Veteran’s for Medical Marijuana

Post Traumatic Stress Disorder (PTSD) wreaks misery on soldiers and families. Military training, combat experience and traumatic events like sexual abuse often radically change cognitive functioning. Unable to process peacetime situations without infusing combat conditioned responses, PTSD sufferers live chaotic, often isolated lives. Approximately 6500 veterans and 349 active service members committed suicide in 2012. The United States Veterans’ Administration (VA) is tasked with providing medical care for all honorably discharged veterans. This includes some psychological care.

A veteran with PTSD faces life and career altering choices. The VA does not dissuade this notion, advising on their website. “You may think that avoiding your PTSD is critical to keeping your job. But if your PTSD symptoms are getting in the way of doing your duties, it is better to deal with them before they hurt your military career. Getting help for PTSD is problem solving.”

The VA outlines several treatments, “cognitive processing, prolonged exposure treatment, mindfulness practice” to name a few, but provides more extensive information for psychiatrists prescribing Selective Serotonin Reuptake Inhibitors (SSRIs), antidepressants and other prescription drugs. “The only two FDA approved medications for the treatment of PTSD are sertraline (Zoloft) and paroxetine (Paxil). All other medication uses are off label, though there are differing levels of evidence supporting their use…” In a series of videos linked to the site, Psychiatrist Matthew J. Friedman of the VA National Center for PTSD explains that his patients “usually use these medications indefinitely.”

“David” is a former Army Corporal 1st Cavalry who served two terms in Iraq as a chaplain’s assistant in a 900 troop infantry unit. He started suffering from night terrors during basic training after performing sleep deprivation exercises. “I’m dead asleep, having a nightmare. They call me back. I try to explain to them that my time is done. Then I’m in Iraq and it’s hitting the fan and I can’t find my weapon! I don’t remember the rest, but if someone comes into my room or makes the slightest noise, I jump up in the fighting position, screaming, cursing, telling them that I am going to rip them in half. I’ve punched people, thrown stuff. My brother has kicked my ass my entire life, whenever it happens he’s terrified.”

Before enlisting, David was a teetotaling Protestant and devout believer in “George Bush, the War in Iraq, all of it.” Responsible for protecting unarmed rabbis, priests, imams and monks as they performed their duties, he screened soldiers seeking spiritual advice to make sure they weren’t a threat. “They told me all the stories, so I know how every one of their buddies died in detail. Then I would prepare their memorial services.” With the clergy’s help, David implemented a system to make sure those close to a fallen comrade didn’t sleep where they could see their friend’s empty bunk, a common trigger for night terrors. Many soldiers were simply “too far gone,” and referred to psychiatrists.

“More often than not, that’s the route that ends up happening. These people cannot handle it. They were not right for the situation. They thought they wanted to kill people without having any idea what that means. And then the reality bomb hit them so hard that they just couldn’t recover from it.”

For David, healing from the trauma of seeing friends grotesquely killed, sexual harassment from a senior officer, a broken engagement during his first tour, and the shock that George Bush was “just a spokesman for the oil industry” was found primarily through frequent sessions “talking for hours with a Rabbinical scholar while smoking joints.” After a few months processing the theological, political and personal ramifications of the war this way, he realized his night terrors were becoming less frequent. “I wasn’t smoking every night, so I didn’t see a correlation that it was stopping the night terrors.”

Four years back in the US and still waking violently to the slightest sound, David “just couldn’t take it anymore” and sought help from the VA. He told a physician’s assistant that he suspected marijuana might be helping, but worried about side effects. “All the research I had done said it was safe. The guy was very casual, but he recommended that I stop using it because they had stuff that would do the trick.”

The assistant prescribed diphenhydramine (Benadryl), an allergy and sleep aid, and “some blood pressure pills to make my heart slow down and stop the nightmares.” The treatment didn’t stop the problem and left him groggy and dysfunctional in the morning. “Benadryl hazes you, whereas weed, especially Sativa, makes me think clearer.”

David worries that he might “start liking marijuana too much and abuse it,” but prefers to take that risk over a lifetime experimenting with prescription medications. “I don’t subscribe to that way of thinking. I am completely 100 percent sure that marijuana cured my night terrors. My brain operates at a higher level than normal about my surroundings and I think about things in a much more peaceful way. My roommates can walk into my room now when I’m asleep and I’m like, “Hey, Dude.”

Years of persistent lobbying by the advocacy group Veterans for Medical Marijuana goaded the US Veteran’s Administration to clarify its stance in a January 2011 memo. “VHA policy does not administratively prohibit Veterans who participate in state marijuana programs from also participating in clinical programs where the use of marijuana may be considered inconsistent with treatment goals. Patients participating in state marijuana programs must not be denied VHA services. If a patient reports participation in a state marijuana program to a member of the clinical staff, that information is entered into the ‘non-VA medication section’ of the patient’s electronic medical record.”

Currently, the medical establishment waits to see if specific molecules can be isolated from cannabis and used to treat specific symptoms. With new strains bred daily across a multi-billion dollar global industry, testing with scientific certainty is an elusive goal. Several small studies are currently being funded and undertaken by federal and private researchers. For veterans and those close to them experiencing PTSD, research into treatment opportunities is crucial to finding a path to recovery.

Experimenting with treatment for mental disorders is extremely dangerous. Cannabis Now does not advocate or repudiate any particular course of treatment, but all available studies have shown that talking to friends, loved ones and professionals about PTSD triggers is vital to recovery. Veterans for Medical Marijuana urges those seeking treatment to, “Be assertive, every veteran deserves any, and all, medical and/or psychological help.”

Looking for more resources?

United States Department of Veteran’s Affairs National Center for PTSD
Veterans for Medical Marijuana Access
Multidisciplinary Association for Psychedelic Studies Medical Marijuana Research Page
PTSD Forum – Chat rooms, information, videos and music
American Academy of Cannabinoid Medicine

This story was originally published in the print edition of Cannabis Now.

The post Coping with Cannabis: A Soldier’s Experience with PTSD appeared first on Cannabis Now.